BRAF and non-small cell lung carcinoma: Conversely, BRAF fusions were rarely detected in 0.2% of a total of 17,128 NSCLC samples, with the most prevalent fusion partners including acylglycerol kinase (AGK), dedicator of cytokinesis protein 4 (DOCK4), and tripartite motif-containing 24 (TRIM24), while the most frequently co-occurring mutations were TP53, CDKN2A, EGFR, and CDKN2B [46].